- Cell/drug delivery
Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery.
- Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® is expected later this year, with an anticipated commercial launch in 2018.
- OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries.
BioTime also has significant equity holdings in two publicly traded companies and one private company:
- Asterias Biotherapeutics, Inc. (NYSE American: AST)
- OncoCyte Corporation (NYSE American: OCX)
- AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
July 17, 2018
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
July 12, 2018